التفاصيل البيبلوغرافية
| العنوان: |
Chitooligosaccharide-modified PLGA-loaded PPD nanoparticles ameliorated sepsis-associated acute kidney injury via the NF-κB signaling pathway. |
| المؤلفون: |
Gong, Baifang1 (AUTHOR), Yu, Yawen1 (AUTHOR), Bai, Xinxin1 (AUTHOR), He, Yaping1 (AUTHOR), Pan, Tao1 (AUTHOR), Liu, Teng1 (AUTHOR), Wang, Zhixia1 (AUTHOR), Liu, Ke2 (AUTHOR), Fan, Huaying1 (AUTHOR) katiefhydong@sina.com |
| المصدر: |
Drug Development & Industrial Pharmacy. Dec2024, Vol. 50 Issue 12, p1008-1020. 13p. |
| مصطلحات موضوعية: |
ACUTE kidney failure, CELLULAR signal transduction, CELL survival, NANOPARTICLES, CLINICAL medicine |
| مستخلص: |
Objectives: Sepsis-associated acute kidney injury (SA-AKI) is a significant clinical challenge with high morbidity and mortality. Low bioavailability of protopanaxadiol (PPD) limits its clinical application. In this study, PPD was encapsulated with chitooligosaccharide (COS) modified polylactic-co-glycolic acid (PLGA) to develop novel nanomedicines for the treatment of SA-AKI. Methods: COS-PLGA-PPD nanoparticles were prepared by emulsified solvent evaporation method, and their properties were evaluated. In vitro, the anti-inflammatory and protective effects of COS-PLGA-PPD NPs were investigated in a cellular model of LPS-induced NRK-52E cells and their uptake in Caco-2 cells. Indicators of renal injury, inflammation, and NF-κB signaling pathway were evaluated by injecting LPS into SD rats and inducing SA-AKI model in vivo. The oral bioavailability of nanoparticles was evaluated by pharmacokinetics. Results: Compared with PPD and unmodified nanoparticles, COS-PLGA-PPD NPs were more stable, with a particle size of 139.69 nm, which enhanced the viability of NRK-52E cells, increased the uptake of Caco-2 cells, alleviated the symptoms of SA-AKI in rats, inhibited the NF-κB signaling pathway, reduced the expression of inflammatory factors, and had a bioavailability 1.7-fold that of PPD. Conclusion: COS-PLGA-PPD NPs ameliorate LPS-induced SA-AKI in rats by inhibiting the NF-κB signaling pathway, providing a basis for the treatment of SA-AKI. [ABSTRACT FROM AUTHOR] |
|
Copyright of Drug Development & Industrial Pharmacy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Business Source Index |